All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Impact Therapeutics (Shanghai) Inc. has divulged substituted tricyclic compounds acting as poly(ADP-ribose) polymerase (PARP; ARTD) inhibitors reported to be useful for the treatment of cancer.
Biofront Ltd. has described proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) targeting moiety via linker acting as HPK1 degradation inducers reported to be useful for the treatment of cancer.
T cells do not have the last word in some breast cancers. According to a study from the University of Pittsburgh, the key to estrogen receptor positive (ER+) breast tumors are macrophages, not T cells, and targeting them could prevent immunotherapy failure in this type of cancer.
Adlai Nortye Pharmaceutical Co. Ltd. has described molecular glue degraders acting as cyclin-dependent kinase 12 (CDK12)/cyclin K degraders reported to be useful for the treatment of cancer, viral infections, autoimmune disease and inflammatory disorders.
Janssen Biotech Inc. and Yuhan Corp. have synthesized substituted aminopyridine compounds acting as EGFR (HER1; erbB1) (mutant) inhibitors reported to be useful for the treatment of cancer and immunological disorders.
RSS
